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Background. Patients seek an eﬀective alternative to pharmacotherapy including herbal treatment options for allergic rhinitis and
rhinosinusitis. Material and Methods. Nasal mucosal tissue was obtained from 12 patients, fragmented, preincubated with tissue
culture medium, S. baicalensis and/or E. senticosus and/or vitamin C (each compound 0.2 μg/mL and 2 μg/mL) for 1 hour at
37◦C/5% CO2, and stimulated with anti-IgE for 30 minutes and 6 hours to imitate the allergic early and late phases. Furthermore,
Staphylococcus aureus superantigen B (SEB) stimulation for 6 hours was used to imitate T-cell activation. Results. The combination
of S. baicalensis and E. senticosus had a more potent suppressive eﬀect on the release of PGD2, histamine, and IL-5 than S. baicalensis
alone. The combination also resulted in a significant inhibition of SEB-induced cytokines comparable or superior to an established
topical corticosteroid, fluticasone propionate. Vitamin C increased ciliary beat frequency, but had no anti-inflammatory eﬀects.
Discussion. The combination of S. baicalensis and E. senticosus may be able to significantly block allergic early-and late-phase
mediators and substantially suppress the release of proinflammatory, and Th1-, Th2-, and Th17—derived cytokines.
1. Introduction
Chronic upper airway diseases such as allergic rhinitis and
chronic rhinosinusitis are common and known to be dis-
abling diseases, and respectively account for 20% and 11%,
of the European adult population [1, 2]. Treatment options
have been summarized in recent guidelines [3, 4], and ev-
idence-based recommendations have been formulated. The
recommended pharmacologic approaches include antihis-
tamines and topical corticosteroids as first choice treatments.
However, patients may reject those treatment options due to
common side eﬀects, lack of eﬃcacy, and a phobia for steroid
use. An increasing number of patients seek an eﬃcacious
alternative, including herbal treatment options [5].
Allergic rhinitis (AR) represents an inflammation of the
nasal mucosa to allergens after a sensitization process. Typi-
cally, symptoms occur rapidly after allergen exposure; sneez-
ing, and itching manifest within seconds or a few minutes,
nasal secretion and obstruction following within 30 minutes.
A second so-called late-phase response with nasal congestion
as the main symptom has been demonstrated, which is par-
alleled by the influx of eosinophils [3]. Mast cells are pivotal
in the immediate response, releasing histamine among other
mediators such as leucotrienes and prostaglandins, and Th2
cells are known to orchestrate the late phase response via the
release of potent cytokines including interleukin IL-4, IL-5,
and IL-13.
Also acute postviral (ARS) and chronic rhinosinusitis
with or without nasal polyps (CRSsP, CRSwNP) are currently
understood to represent an inflammatory reaction, orches-
trated by either Th1, Th2, or Th17 cells, consequently involv-
ing other cell types such as neutrophilic or eosinophilic gran-
ulocytes [4]. Although the resulting tissue environment may
be clearly diﬀerent between those inflammatory reactions,
they do share similarities such as the involvement of proin-
flammatory cytokines formed within the mucosa.
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The above elicited pathophysiologic responses are best
observed in the human subject as is their response to specific
therapies aimed to treat the underlying pathogen. However,
for purposes of medicinal evaluations and showing the eﬀect
of new therapeutic agents a less invasive and risk-free model
is needed to show eﬀective response. Towards that end, we
developed ex vivo mucosal tissue models using human nasal
mucosa freshly harvested during routine nasal and sinus
surgery [6, 7]. These models have been specifically stipulated
to be used for allergic conditions making use of leucotriene
de novo synthesis of mast cells, or T helper cell biased in-
flammatory conditions measuring cytokines derived from
diﬀerent T helper cells as outcome parameters. Diﬀerent
stimuli have been identified for the various conditions [6, 8].
Furthermore, standard drugs currently used in such con-
ditions (e.g., topical corticosteroids in allergic rhinitis and
acute or chronic rhinosinusitis) with a known response can
be used to compare the newly tested therapy facilitating the
assessment of eﬀect and the therapeutic potential of the “new
arrival”.
Over the last two decades interest has mounted regarding
the mechanism of action of herbal therapies [5, 9]. Many
attempts to identify the active components of herbal reme-
dies have concluded that in general no one component is
responsible for the therapeutic capacity, but rather a com-
plex and intricate interaction of various herbs may result
in therapeutic eﬃcacy. Additionally, many of these herbal
combinations have begun to demonstrate anti-inflammatory
actions. Although the majority of herbal medications are
delivered orally, topical applications have also been practiced.
We researched the literature for herbal compounds that
have inhibitory eﬀect on the release of mediators and cyto-
kines typically involved in upper airway disease such as aller-
gic rhinitis and rhinosinusitis. Of the various herbal entities
considered, Scutellaria baicalensis and Eleutherococcus senti-
cosus have been reported to elicit eﬀects on inflammation,
especially of allergic origin [10–13].
In an environmentally induced inflammation model, S.
baicalensis had significant anti-inflammatory eﬀects by in-
hibiting the NF-κB pathway [14]; these observations were
recently extended to IKKαβ and Iκ-Bα, further supporting
the potent anti-inflammatory activity through the MAP
kinase pathway [15]. In skin-inflammation models (atopic
dermatitis), S. baicalensis modulated immunological re-
sponses mainly through influencing IL-5 or IL-10 levels [16],
inhibited prostaglandin E2 generation, and suppressed the
expression of proinflammatory genes, cyclooxygenase-2, and
interleulin-1beta in the skin lesion [17]. Also, E. senticosus
inhibited mast cell-mediated anaphylaxis in a murine model
[18] and significantly attenuated LPS-induced iNOS expres-
sion by blocking transcription pathways in macrophages
[19].
After screening these herbal compounds, we created a
formula which includes S. baicalensis, E. senticosus, and vita-
min C. This combination demonstrated a reproducible and
meaningful eﬀect on mast cell and T cell mediators.
Our objective was to show the anti-inflammatory eﬀect
of this herbal/vitamin formulation in comparison to flutica-
sone propionate, a well-established topical corticosteroid for
the treatment of upper airway inflammation [6], in our ex
vivo human mucosal model.
2. Materials and Methods
2.1. Patients. Nasal mucosal tissue was obtained from a to-
tal of 12 patients (mean age 44 years, range 22 to 67 years)
during routine sinus surgery, who either had a septal devia-
tion and conchal hypertrophy resulting in nasal obstruction
(n = 6 for inferior turbinate tissue, used for mast cell
related experiments) or nasal polyps (n = 6 for polyp tissue,
used for mast cell-and T-cell-related experiments), at the
Department of Otorhinolaryngology of the University Hos-
pital of Ghent. The ethical committee of the Ghent University
Hospital approved the study, and all patients gave their
written informed consent prior to inclusion in the study.
None of the subjects received intranasal corticosteroids,
anti-histamines, anti-leukotrienes, oral or intranasal decon-
gestants, or intranasal anticholinergics within the 2 weeks
prior to surgery. None of the subjects received oral and/or
intramuscular corticosteroids within the 4 weeks prior to
surgery. The female subjects who were pregnant or breast-
feeding were excluded from the study. Nasal polyps were
diagnosed based on symptoms, clinical examination, nasal
endoscopy, and sinus computed tomography (CT) scan ac-
cording to the EP3OS guidelines [3]. Inferior turbinate hy-
pertrophy was diagnosed by nasal endoscopy. Patients were
included independent of their atopic status.
2.2. Mechanical Disruption and Stimulations of Human Nasal
Tissue. The human nasal mucosa and submucosa was cut
thoroughly in tissue culture medium consisting of RPMI
1640 (Sigma-Aldrich, Bornem, Belgium), containing 2 mM
LGlutamine (Invitrogen, Merelbeke, Belgium), antibiotics
(50 IU/mL penicillin and 50 μg/mL streptomycin) (Invitro-
gen), and 0.1% BSA (Bovine Serum Albumin, Sigma).
The tissue was passed through a mesh to achieve com-
parable fragments. The tissue fragments (±0.9 mm3) were
weighed and resuspended as 0.04 g tissue/1 mL tissue culture
medium and preincubated with tissue culture medium, S.
baicalensis and/or E. senticosus and/or vitamin C (each com-
pound 0.2 μg/mL and 2 μg/mL) for 1 hour at 37◦C/5% CO2.
For anti-IgE stimulations, the tissue was preincubated for 1
hour at 37◦C, 5% CO2 with 1 μg/mL human myeloma IgE
(Calbiochem, VWR International, Leuven, Belgium). After
3 washing steps the tissue fragments were resuspended in
the appropriate amount of culture medium, and 0.5 mL of
this fragment suspension was dispensed per well of a 48-well
plate. (BD Falcon, VWR, Leuven, Belgium).
2.3. Models for Mast Cell Degranulation and T-Cell Activation.
The models for mast cell degranulation and T-cell activation
were used as described before [6–8]. For mast cell-related
stimulations, the fragment suspensions were stimulated with
either culture medium (negative control) or ε-chain specific
anti-human IgE antibody (Dako Belgium N.V., Heverlee,
Belgium) at 10 μg/mL (Dako Belgium N.V., Heverlee, Bel-
gium) for 30 minutes. Supernatants were separated by
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centrifugation and stored immediately at −20◦C until anal-
ysis of histamine and PGD2. Concentrations of histamine
and PGD2 were measured in tissue supernatants obtained
after the stimulations using ELISA kits for Histamine (IBL
Hamburg, Germany; detection limit 2.7 ng/mL) and PGD2
(Cayman Chemicals, Ann Arbor, Michigan; detection limit
2 pg/mL) following the instructions of the manufacturer.
For T-cell-related stimulations, tissue fragments were
stimulated with culture medium (negative control), 0.5 mg/
mL staphylococcus aureus enterotoxin B (SEB, Sigma-Al-
drich), or ε-chain-specific anti-human IgE antibody (Dako
Belgium N.V., Heverlee, Belgium) at 10 μg/mL (Dako Bel-
gium N.V., Heverlee, Belgium) for 6 hours. Supernatants
were separated by centrifugation; aliquots of the super-
natants were stored immediately at −20◦C until analysis
of cytokines. Concentrations of IL-1β, TNF-α, IFN-γ, IL-2,
IL-5, and IL-17 (detection limits 0.6 to 7.8 pg/mL) were
measured in tissue supernatants obtained 6 h after the ex
vivo stimulations using commercially available ELISA kits
(Quantikine ELISA, R&D Systems, Minneapolis, Minn) fol-
lowing the instructions of the manufacturer. The topical glu-
cocorticosteroid fluticasone propionate was used as a positive
control in concentrations of 10−10 to 10−8 molar for all
stimulations with SEB. Tissues were incubated with either
single compounds or the final combination of herbs for 1
hour prior to stimulations.
2.4. Toxicity and Ciliary Beat Frequency. Peripheral blood
mononuclear cells (PBMCs) consisting mainly of monocytes,
T cells, and B cells and smaller amounts of NK cells and den-
dritic cells of both myeloid and plasmacytoid origin of 3
donors were used for the assessment of potential toxic risks of
the used compounds. PBMCs were incubated in the presence
or absence of compounds, either single or in combination,
and cell viability was analysed by trypan blue exclusion.
Preservation of ciliary function was tested utilizing the
Sissons Ammons Video Analysis (SAVA) system; we evalu-
ated the acute eﬀects of the herbal preparations at diﬀerent
concentrations on freshly harvested mouse nasal septa. Base-
line cilia beat frequency was obtained for 10 minutes prior
to application of the herbal extracts. Cilia beat frequency
was continuously monitored for an additional 15 minutes
following application of the test substances.
2.5. Statistical Analysis. Statistical analysis was performed
using the Wilcoxon test (for paired comparisons). The Mann-
WhitneyU test was used for between-group (unpaired) com-
parisons. P values of less than 0.05 were considered statisti-
cally significant.
3. Results
3.1. Mast Cell-Related Mediators: Prostaglandin D2 and His-
tamine (Figure 1). Anti-IgE resulted in a significant increase
in prostaglandin D2 (PGD2) and histamine release within
30 minutes of tissue exposure in both inferior turbinate and
nasal polyp mucosal tissue. In comparison to tissue culture
medium, S. baicalensis, but not E. senticosus, significantly
reduced the release of de novo synthesized PGD2 at a con-
centration of 20 μg/mL in inferior turbinates and 2 μg/mL in
nasal polyps. S. baicalensis at this concentration also reduced
the release of histamine in stimulated nasal polyps.
The combination of S. baicalensis and E. senticosus,
however, had a more potent eﬀect on the release of PGD2 in
inferior turbinate tissue (significance reached for 2 μg/mL for
each component) and nasal polyps (1 μg/mL); a concentra-
tion of 0.2 μg/mL totally suppressed the release of PGD2 from
nasal polyp tissue after anti-IgE stimulation (Figure 1(a)).
Similarly, S. baicalensis, but not E. senticosus, induced
a significant and nearly complete suppression of anti-IgE-
induced histamine release in nasal polyps at a concentration
of 20 μg/mL. The combination of S. baicalensis and E. sen-
ticosus, however, had a similarly strong suppressive eﬀect on
histamine release with only 0.2 μg/mL of each compound
(Figure 1(b)).
Vitamin C alone or in combination with S. baicalensis or
E. senticosus did not show any additional significant eﬀect on
the release of PGD2.
3.2. Anti-IgE Induced Cytokine Release (Figure 2). Anti-IgE
stimulation of nasal polyps resulted in an increase in IL-5
within 6 hours; this release could significantly be suppressed
by corticosteroid pretreatment. Furthermore, the combina-
tion of S. baicalensis and E. senticosus, but no single com-
ponent, resulted in a significant inhibition of IL-5 release at
a concentration of 2 μg/mL of each component.
3.3. T-Cell Activation-Related Release of Cytokines (Figure 3).
Spontaneous release of IL-5, and TNF-α could be observed
in nasal polyp tissue, which was significantly inhibited by
the combination of S. baicalensis and E. senticosus, but no
single component, at a concentration of 2 μg/mL of each
component (data not shown).
SEB resulted in a significant release of IL-1, TNF-α,
IFN-γ, Il-2, IL-5 and IL-17 from nasal polyp tissue, indi-
cating the stimulation of all prominent T helper cell popu-
lations. Although single components demonstrated suppres-
sive activity, this suppression remained insignificant; only
the combination of S. baicalensis and E. senticosus at a con-
centration of 2 μg/mL of each component resulted in a
significant, nearly complete suppression of the release of
IFN, IL-5, IL-1β, and TNF-α 6 h after SEB-release, and a
partial suppression for IL-17 and IL-2 (Figure 3(a)). The
suppressive activity was superior to that of an established
topical corticosteroid, fluticasone propionate, for IFN-γ, IL-
1β, TNF-α, and IL-17 and equivalent for IL-5 and IL-2
(Figure 3(b)).
Vitamin C alone or in combination with S. baicalensis or
E. senticosus had no significant eﬀect on the release of cyto-
kines in this model.
3.4. Toxicity, Ciliary Beat Frequency. The pH assessments
showed normal, physiological values for all dilutions used.
There was no toxicity of the compounds, either single or
in combination, at concentrations lower than or equal to
10 μg/mL. SEB as well as higher concentrations of the mix
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Figure 1: Mast cell-related mediators: Prostaglandin D2 (a) and histamine (b). Anti-IgE resulted in a significant increase in prostaglandin D2
(PGD2) and histamine release within 30 minutes after tissue exposure in nasal polyp mucosal tissue. In comparison to tissue culture medium,
S. baicalensis, but not E. senticosus (data not shown), significantly reduced the release of de novo synthesized PGD2 at a concentration of
2 μg/mL (high) in nasal polyps. The combination of S. baicalensis and E. senticosus, however, had a more potent eﬀect on the release of PGD2
in nasal polyp tissue and reached significance already at a low concentration of 0, 2 μg/mL of each compound after anti-IgE stimulation (a).
The combination of S. baicalensis and E. senticosus had a similarly strong suppressive eﬀect at a low concentration of 0.2 μg/mL to reduce the
release of histamine (b).
induced a mild toxicity (less than 15% of cells were apoptot-
ic).
Application of the highest concentration of the combina-
tion of S. baicalensis and E. senticosus did not aﬀect ciliary
beat frequency. However, vitamin C significantly increased
ciliary beat frequency from a concentration of 0.1%. This
eﬀect was not diﬀerent when vitamin C was applied in com-
bination with the herbal compounds.
4. Discussion
We here present a human nasal mucosal model which allows
testing of drug compounds in several aspects; we demon-
strated the ability of a herbal composition to inhibit the
release of allergic immediate and late-phase mediators as well
as the release induced by the activation of diﬀerent T cells.
We were able to establish that preincubation of S. baicalensis
for one hour is able to significantly suppress the release of
histamine and PGD2 upon anti-IgE stimulation of mucosal
tissue and that the combination of S. baicalensis with E.
senticosus and vitamin C increases the suppressive eﬃcacy of
PGD2 and histamine. This combination was shown to low-
er the concentrations and nearly completely suppress both
PGD2 and histamine.
In line with these findings, within 6 hours after stimula-
tion, anti-IgE-induced release of IL-5 was significantly sup-
pressed by the herbal combination. Furthermore, the herbal
combination, but no single component on its own, was able
to inhibit a wide range of T eﬀector cells to release specific
cytokines upon SEB stimulation, including Th1, Th2 and
Th17 cells. This eﬀect was partially superior, but certainly
equivalent to the activity of topical corticosteroids in terms
of the range and the degree of suppression of cytokines.
Stimulations with anti-IgE on IgE-primed nasal tissue
fragments lead to a concentration-dependent release of his-
tamine, leukotrienes, and PGD2 in our mucosal model, as
was described earlier [7]. The release of these early-phase
mediators was significantly higher in nasal polyps compared
to inferior turbinates, although tryptase, Fc epsilon RI alpha
positive cells, and Fc epsilon RI alpha-chain transcripts were
equally present in both groups. Thus, nasal polyp tissue
would be especially suitable for tissue stimulation assays,
with a more robust read-out allowing comparative studies
using diﬀerent compounds. We tested diﬀerent tissues, infe-
rior turbinate, and nasal polyp mucosa and showed similar
results, confirming the findings. Again, the finding of a sup-
pression of PGD2 and histamine release points to a mast cell
stabilizing and not just de novo synthesis of PGD2-inhibiting
eﬀect of S. baicalensis as single compound, but also as the
most eﬀective component in the herbal combination.
In an independent set of studies, we demonstrated that a
Syk inhibitor prevented mast cell degranulation assessed by
the measurement of histamine release and the production
of PGD2 [8]. Furthermore, the Syk inhibitor was similarly
able to significantly inhibit the release of these granules and
newly synthesized mediators by nasal polyp mast cells in
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Figure 2: Anti-IgE-induced cytokine release. Anti-IgE stimulation
of nasal polyps resulted in an increase in IL-5 within 6 hours.
The combination of S. baicalensis and E. senticosus, but no single
component, resulted in a significant inhibition of IL-5 release at a
concentration of 2 μg/mL of each compound.
a dose-dependent manner. These studies show the robustness
of the mucosal tissue assays and their usefulness to test mast
cell-related therapeutic approaches in human tissue ex vivo.
The release of IL-5 several hours after anti-IgE stimula-
tion has been described as part of the late-phase allergic reac-
tion, related to the influx and activation of eosinophilic gran-
ulocytes, for which IL-5 is a key survival and proliferation
factor [3, 20]. The combination of these eﬀects—suppression
of early-and late-phase allergic mediators—by one herbal
composition may be of great relevance in the treatment of
allergic diseases such as allergic rhinitis, as it would target
sneezing and secretion as well as nasal obstruction typically
developing over minutes and hours upon exposure to the
allergen; such an approach would have a fast onset of action
by suppressing the release of histamine, and at the same time
a high anti-inflammatory eﬃcacy by inhibition of the allergic
eosinophilic response.
Apart from mast cell-derived cell products, the herbal
composition also significantly inhibited the SEB-induced
activation of diﬀerent T-cell subsets. In former studies we
have shown that the activation of T cells by SEB is a relevant
naturally occurring event in the airways (refs), resulting in
the activation of Th1, Th2, Th17, and other cells and that na-
sal polyp tissue is a suitable model tissue for exposure tests,
as they comprise a vast range of diﬀerent T cell subsets [6].
T-cells orchestrate immune defence and inflammation; cur-
rently, 3 major T eﬀector cells are described (Th1, Th2, and
Th17 cells). These cells are important in diﬀerent forms of
inflammation and substantially impact the composition of
inflammatory cells (eosinophilic versus neutrophilic), and
also induce pathogenic changes such as mucus production
and remodelling [21]. Th2, Th1, and Th17 cells have been
implicated in chronic diseases of the paranasal sinuses, that
is, Th1-related cytokine IFN-γ in chronic rhinosinusitis
without nasal polyps (CRSsNP), Th2-related cytokines IL-4
and IL-5 in CRS with nasal polyps (CRSwNP), and recently
Th17-cell-related IL-17 in Asian nasal polyps and polyps in
cystic fibrosis patients [22, 23]. As those cytokines may also
present within the same tissue, a drug with a broad range
of activities on diﬀerent T cells is needed to eﬃciently down-
regulate inflammation.
Recent findings demonstrate that the specific activation
of the inflammatory pathway by superantigens such as SEB
results in a severe local inflammation and the systemic spread
of disease, such as asthma in nasal polyp patients [24–26].
Although topical corticosteroids are a mainstay for the treat-
ment of airway inflammation, and nasal polyps specifically,
they do have merits—the nearly complete suppression of Th2
cells—and deficits in terms of an incomplete suppression of
Th1 and Th17 responses. Thus, as several T-cell subsets may
drive inflammation in a given disease, a broader spectrum
of activities targeting possibly all T-cell subsets may be
advantageous for a drug.
We demonstrated that a herbal combination is able to
significantly suppress the release of proinflammatory cytoki-
nes such as IL-1 and TNF-α, the general T-helper cell marker
IL-2, but also specific T-cell markers IFN-γ, IL-5, and IL-17
from nasal polyp tissue upon SEB stimulation, indicating
the suppression of all prominent T helper cell populations.
The combination of S. baicalensis and E. senticosus at a con-
centration of 10 μg/mL resulted in a significant, nearly com-
plete, suppression of Th1 and Th2 cells and a partial sup-
pression of Th-17 cells. The suppressive activity was not
inferior and could be considered to be superior to that of an
established topical corticosteroid, fluticasone propionate
(FP), for IL-1β, TNF-α, IL-2, IFN-γ, IL-5, and IL-17. Fur-
thermore, the herbal product could be shown to be nontoxic
to the mucosa, and even mildly stimulating the cilia beat
frequency, leading to a faster clearance of the mucociliary
transport.
There is evidence from other sources that the single com-
pounds used here do have anti-inflammatory activities. S.
baicalensis is one of the most popular and multi-purpose
herbs used in China traditionally for treatment of inflamma-
tion and bacterial and viral infections; it has a strong anti-
inflammatory activity and low toxicity. The bioactive com-
ponents of Scutellaria have been confirmed to be flavones
[27]. Scutellaria baicalensis Georgi has been used as an anti-
inflammatory and anti-allergic agent in the treatment of a
variety of inflammatory diseases such as bronchitis, asthma,
and atopic dermatitis [10, 11].
E. senticosus, also known as “Siberian ginseng”, in a com-
bination with other herbs proved superior to conventional
antiviral medications for reducing severity and duration of
influenza infections in a study by Kulichenko et al. [12].
Recently Jung et al. published findings demonstrating robust
reduction of inflammatory parameters, including IL-6, TNF-
α, neutrophil density, and prostaglandin E2 in a mouse air
pouch inflammatory model [13]. Two of the three herbals
used by Jung et al. were S. baicalensis and E. senticosus.
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Figure 3: Continued.
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Figure 3: T-cell activation-related release of cytokines. (a) SEB resulted in a significant release of IL-1, TNF-α, IFN-γ, IL-2, IL-5, and IL-17
from nasal polyp tissue, indicating the stimulation of all prominent T helper cell populations. Although single components demonstrated
suppressive activity, this suppression remained insignificant; only the combination of S. baicalensis and E. senticosus at a concentration of
2 μg/mL of each compound resulted in a significant, nearly complete suppression of the release of IFN, IL-5, IL-1β and TNF-α 6 h after
SEB stimulation, and a partial suppression for IL-17 and IL-2. (b) The suppressive activity of the combination was superior to that of an
established topical corticosteroid, fluticasone propionate (FP), for IFN-γ, IL-1β, TNF-α, and IL-17 and equivalent for IL-5 and IL-2.
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Although vitamin C was not shown to add to the benefit
of the herbal compounds in terms of reduction of mediator
release from mast cells or cytokine release from T cells, vita-
min C has an eﬀect on the ciliary beat frequency. This eﬀect
may counteract the reduction of mucociliary clearance in
allergic rhinitis and contribute to avoid an impairment of
clearance in chronic sinus disease [28].
These findings indicate that the herbal composition may
represent a promising therapeutic approach for airway dis-
eases including allergic rhinitis, as it demonstrates a double
interference with early-and late-phase reactions (involving
mast cells and eosinophils) ex vivo, but also may include
acute rhinosinusitis, chronic rhinosinusitis (both involving
Th1 cytokines), and nasal polyps (a mostly Th2-driven dis-
ease in Caucasians) by its suppressive activity on cytokine
release in the human mucosal model. Also, in comparison
with topical corticosteroids, the composition is therefore
uniquely positioned to act as a topically applied anti inflam-
matory agent in nasal allergies, chronic and acute rhinosi-
nusitis, nasal polyp disease, and eventually also lower airway
disease such as asthma and COPD. Similarly, it may be
beneficial in the therapy of other inflammatory conditions
unrelated to the airways, if suﬃcient concentrations can be
achieved via oral route. Our findings merit further evaluation
in patient populations, to establish the clinical relevance and
the clinical eﬀect of our ex vivo tested formula.
5. Conclusions
We show in an ex vivo human nasal mucosal model that a
combination of S. baicalensis, E. senticosus, and vitamin C
may be able to significantly block allergic early and late phase
mediators and substantially suppress the release of proin-
flammatory, Th1-, Th2-and Th17- derived cytokines, at least
comparable to a topical corticosteroid. These findings sup-
port further research with these herbal compounds in clinical
studies including allergic rhinitis, and acute and chronic
rhinosinusitis.
Abbreviations
AR: Allergic rhinitis
ARS: Acute rhinosinusitis
CRS: Chronic rhinosinusitis
CRSsNP: Chronic rhinosinusitis without nasal
polyps
CRSwNP: Chronic rhinosinusitis with nasal polyps
FP: Fluticasone propionate
IFN: Interferon
IL: Interleukin
PGD2: Prostaglandin D2
Th: T helper
TNF: Tumor necrosis factor
S. baicalensis: Scutellaria baicalensis
E. senticosus: Eleutherococcus senticosus.
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